Page 1 of 15

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13D


                   Under the Securities Exchange Act of 1934


                               CONMED Corporation
                                (Name of Issuer)


                         Common Stock, $0.01 par value
                         (Title of Class of Securities)


                                    20741010
                                 (CUSIP Number)


                                  Zimmer, Inc.
                            727 North Detroit Street
                           Warsaw, Indiana 46850-0708
                                 (219) 267-6131
            (Name, Address and Telephone Number of Person Authorized
                     to Receive Notices and Communications)


                                  July 1, 1992
                         (Date of Event which Requires
                           Filing of this Statement)


If the filing person has previously  filed a statement on Schedule 13G to report
the  acquisition  which  is the  subject  of  this  Statement  because  of  Rule
13d-1(b)(3) or (4), check the following box: o

Check the following box if a fee is being paid with this Statement: |X|

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934, as amended (the "Exchange  Act"), or otherwise  subject to the liabilities
of that section of the Exchange Act but shall be subject to all other provisions
of the Exchange Act.



                                                                    Page 2 of 15

                                  SCHEDULE 13D

- -----------------------------------------------

         CUSIP No.  20741010

- -----------------------------------------------


 1       NAME OF REPORTING PERSON
         S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

           ZIMMER, INC.
           I.R.S. Employer Identification Number 13-2695416
- --------------------------------------------------------------------------------


 2       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                (a) o
                                                                         (b) |X|
- --------------------------------------------------------------------------------


 3       SEC USE ONLY

- --------------------------------------------------------------------------------


 4       SOURCE OF FUNDS

           OO

- --------------------------------------------------------------------------------


 5       CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED            o
         PURSUANT TO ITEMS 2(d) OR 2(e)
- --------------------------------------------------------------------------------


 6       CITIZENSHIP OR PLACE OF ORGANIZATION

           Delaware
- --------------------------------------------------------------------------------


  NUMBER OF                7        SOLE VOTING POWER
   SHARES                           698,698
 BENEFICIALLY              8        SHARED VOTING POWER
  OWNED BY                          0
    EACH                   9        SOLE DISPOSITIVE POWER
   PERSON                           698,698
    WITH                  10        SHARED DISPOSITIVE POWER
                                    0
- --------------------------------------------------------------------------------


11       AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

           698,698
- --------------------------------------------------------------------------------


12       CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
- --------------------------------------------------------------------------------


13       PERCENT OF CLASS REPRESENTED BY AMOUNT ON ROW (11)

           5.9%

- --------------------------------------------------------------------------------


14       TYPE OF REPORTING PERSON

           CO
- --------------------------------------------------------------------------------



CUSIP No.  20741010                                                 Page 3 of 15


Item 1.  Security and Issuer.

                  The class of equity securities to which this Statement relates
is the common stock, par value $0.01 per share (the "Common  Stock"),  of CONMED
Corporation,  a New York  corporation  (the  "Issuer"),  which has its principal
executive offices at 310 Broad Street, Utica, New York 13051.

Item 2.  Identity and Background.
                  This  Statement  is being  filed by Zimmer,  Inc.,  a Delaware
corporation  (the  "Company"),  and a wholly-owned  subsidiary of  Bristol-Myers
Squibb Company, a Delaware  corporation  ("Bristol-Myers  Squibb").  The Company
conducts its principal  business and maintains its principal office at 727 North
Detroit Street,  Warsaw,  Indiana  46850-0708.  The Company  designs,  develops,
manufactures  and  sells  surgical  instruments  and  accessories,   orthopaedic
implants,   hospital  oriented  medical  devices  and  disposable  patient  care
supplies.
                  The name,  business address,  present principal  occupation or
employment and citizenship of each executive officer and director of each of the
Company and  Bristol-Myers  Squibb are set forth on  Schedule A hereto  which is
incorporated herein by reference.
                  During the past five years, neither the Company, Bristol-Myers
Squibb  nor,  to the best  knowledge  of the  Company,  any of their  respective
executive officers or directors (i) has been convicted in a criminal  proceeding
(excluding traffic violations or similar  misdemeanors) or (ii) was a party to a
civil proceeding of a judicial or administrative body of competent  jurisdiction
and, as a result of such proceeding,  was or is subject to a judgment, decree or
final  order  enjoining  future  violations  of,  or  prohibiting  or  mandating
activities subject to, federal or state securities laws or finding any violation
with respect to such laws.




CUSIP No.  20741010                                                 Page 4 of 15


Items 3.  Source and Amount of Funds or Other Consideration.
                  The Company  beneficially  owns 698,698 shares of Common Stock
pursuant to a Warrant to Purchase Common Stock, dated as of August 31, 1989 (the
"Warrant"),  issued by the Issuer to the  Company  as a portion of the  purchase
price  paid by the  Issuer  to the  Company  in  connection  with  the  Issuer's
acquisition of Aspen Laboratories,  Inc., then a wholly-owned  subsidiary of the
Company,  in August 1989.  The Warrant is exercisable by the Company at any time
or times on or after  September  1,  1992 but not  after  August  31,  2000 at a
current  purchase  price of $4.2937  per share in cash.  The number of shares of
Common Stock  covered by the Warrant and the purchase  price per share of Common
Stock  are each  subject  to  adjustment  from time to time  pursuant  to and in
accordance with the terms of the Warrant.

Item 4.  Purpose of Transaction.
                  On August 24, 1989,  the Company and the Issuer entered into a
Stock Purchase Agreement (the "Stock Purchase  Agreement") pursuant to which the
Issuer  purchased from the Company all of the issued and  outstanding  shares of
capital  stock of Aspen  Laboratories,  Inc.  Pursuant to the terms of the Stock
Purchase  Agreement,  the  purchase  price  paid by the  Issuer  to the  Company
consisted of both cash consideration and the Warrant.
                  The Warrant is currently  exercisable  in whole or in part for
698,698  shares  of  Common  Stock  at a price of  $4.2937  per  share.  Certain
registration rights are afforded the Company under the terms of the Warrant. The
number of shares of Common Stock and the exercise price per share are subject to
adjustment for stock splits, dividends, distributions and



CUSIP No.  20741010                                                 Page 5 of 15


combinations.  A further  adjustment of the exercise price per share is provided
in the  Warrant in the event of the  granting  of rights or options  (other than
pursuant to the  Issuer's  1983  Employee  Stock Option Plan) or the issuance or
sale by the Issuer of shares of capital  stock at a price  lower than the market
price (as defined) or the exercise  price.  Except under limited  circumstances,
any unexercised portion of the Warrant will expire on August 31, 2000.
                  In connection with the issuance of the Warrant,  Bristol-Myers
Squibb and the Issuer  entered  into an  Agreement,  dated as of August 31, 1989
(the  "Agreement"),  pursuant to which  Bristol-Myers  Squibb agreed that,  once
Bristol-Myers Squibb or any of its subsidiaries  exercised the Warrant and owned
shares of Common Stock (the  "Warrant  Shares"),  Bristol-Myers  Squibb would be
present,  or would cause its  subsidiaries  which own the  Warrant  Shares to be
present,  at  all  stockholder  meetings  of  the  Issuer  for  the  purpose  of
determining the presence of a quorum at such meetings. Bristol-Myers Squibb also
therein  agreed that in the event  Bristol-Myers  Squibb  elects not to vote all
Warrant  Shares on any matter put to a stockholder  vote in accordance  with the
recommendation  of the Board of  Directors  of the  Issuer,  then  Bristol-Myers
Squibb  shall  vote  or  cause  to be  voted  all  Warrant  Shares  in a  manner
proportionate  to the vote of all other  stockholders of the Issuer with respect
to any matter put to a  stockholder  vote.  The  Agreement  terminates  upon the
earlier of August 31,  2003 and the date on which  Bristol-Myers  Squibb and its
subsidiaries no longer hold or own the Warrant or any Warrant Shares.
                  The  Warrant  and the  Warrant  Shares  (when  issued upon the
exercise of the Warrant)  were acquired by the Company for  investment  purposes
only.



CUSIP No.  20741010                                                 Page 6 of 15


Item 5.  Interest in Securities of the Issuer.
                  To  the  best  knowledge  of  the  Company,   the  Issuer  has
outstanding  11,095,786 shares of Common Stock.  Under the terms of the Warrant,
the  Company  beneficially  owns  698,698  shares of Common  Stock  representing
approximately 5.9% of the outstanding shares of Common Stock of the Issuer after
giving  effect to exercise  of the Warrant in full.  Except as set forth in this
Item 5 and on  Schedule  B  attached  hereto  which is  incorporated  herein  by
reference, neither the Company, Bristol-Myers Squibb, nor, to the best knowledge
of the Company, any of their respective executive officers or directors owns any
shares of Common Stock.
                  If the Company  were to  exercise  the Warrant in full (i) the
Company  would  have the sole  power to vote or to  direct  the vote of  698,698
shares of Common Stock and (ii) the Company would have the sole power to dispose
or direct the disposition of 698,698 shares of Common Stock.
                  Except as set forth on  Schedule  B attached  hereto  which is
incorporated herein by reference, neither the Company, Bristol-Myers Squibb nor,
to the best knowledge of the Company, any of their respective executive officers
or directors has effected any  transaction  in shares of Common Stock during the
past sixty (60) days.
                  The Issuer is currently in the process of  registering  shares
of its Common Stock in connection with an  underwritten  public offering of such
Common Stock for cash proceeds payable to the Issuer (the "Offering").  Pursuant
to, and in accordance with the terms of, the Warrant,  the Company has exercised
its  registration  rights  with  respect  to all of the  shares  covered  by the
Warrant, and intends to sell all such shares as part of the Offering.



CUSIP No.  20741010                                                 Page 7 of 15


Upon  completion  of the  Offering,  the Company  shall cease to be a beneficial
owner of securities of the Issuer.

Item 6.  Contracts, Arrangements, Understanding or Relationships With Respect to
         Securities of the Issuer.
                  Except for the  Warrant,  each of the  Company,  Bristol-Myers
Squibb and, to the best  knowledge of the Company,  their  respective  executive
officers  and  directors  is  not  a  party  to  any  contracts,   arrangements,
understandings  or  relationships  (legal or  otherwise)  with any  person  with
respect to any securities of the Issuer.

Item 7.  Material to be Filed as Exhibits.
         Exhibit 1.        Stock  Purchase  Agreement,  dated as of  August  24,
                           1989, between Zimmer, Inc. and CONMED Corporation for
                           all  of  the   outstanding   Common  Stock  of  Aspen
                           Laboratories,  Inc.  (Incorporated  by  reference  to
                           Exhibit  10.2 to  CONMED  Corporation's  Registration
                           Statement on Form S-2 (File No. 33-40455).)

         Exhibit 2.        Warrant to Purchase  Common  Stock,  dated August 31,
                           1989,  issued by CONMED  Corporation to Zimmer,  Inc.
                           covering   shares   of   Common   Stock   of   CONMED
                           Corporation.  (Incorporated  by  reference to Exhibit
                           4.6 to CONMED Corporation's Registration Statement on
                           Form S-2 (File No. 33-40455).)



CUSIP No.  20741010                                                 Page 8 of 15


                                   SIGNATURE
                  After  reasonable  inquiry and to the best of my knowledge and
belief,  I certify  that the  information  set forth in this  Statement is true,
complete and correct.

Dated:  February 6, 1996
                                    ZIMMER, INC.

                                    By:/s/ Timothy M. Wendt
                                       ---------------------
                                       Timothy M. Wendt
                                       Senior Vice President



CUSIP No.  20741010                                                 Page 9 of 15

                                   SCHEDULE A

                  The following  information  sets forth the name,  citizenship,
business address and present  principal  occupation of each of the directors and
executive  officers  of  the  Company  and  Bristol-Myers  Squibb.  Each  of the
directors and executive  officers of the Company and  Bristol-Myers  Squibb is a
citizen of the United States,  except for Joachim H. von Roy who is a citizen of
Germany. Each of the Company's executive officer's business address is 727 North
Detroit  Street,  Warsaw,  Indiana  46580,  and each of  Bristol-Myers  Squibb's
executive  officer's  business  address is 345 Park Avenue,  New York,  New York
10154, in either case unless otherwise indicated.

Name and Business Address           Present Principal Occupation
Directors of Zimmer, Inc.

Terence N. Furness                  President

Michael F. Mee                      Vice President, Zimmer; Chief Financial
                                    Officer and Senior Vice President,
                                    Bristol-Myers Squibb Company

David L. Zabor                      Senior Vice President and Assistant 
                                    Treasurer

Officers of Zimmer, Inc.

Terence N. Furness                  President

Roy D. Crowninshield                Senior Vice President

David L. Zabor                      Senior Vice President and Assistant 
                                    Treasurer

Michael F. Mee                      Vice President 

Stephen Chesnoff                    Vice President and Assistant Secretary
                                           

Jack D. Shinneman                   Vice President

Mark D. Speaker                     Vice President and Assistant Secretary
                                           

Timothy M. Wendt                    Vice President and Assistant Secretary



CUSIP No.  20741010                                                Page 10 of 15


Alice C. Brennan                    Secretary

Harrison M. Bains, Jr.              Treasurer

Dominic Mezzapelle                  Assistant Secretary

Directors of Bristol-Myers Squibb   
Company

Charles A. Heimbold, Jr.            Chairman of the Board, President and Chief
Bristol-Myers Squibb Company        Executive Officer
345 Park Avenue
New York, New York 10154

Robert E. Allen                     Chairman and Chief Executive Officer of
AT&T Corp.                          AT&T Corp.
295 North Maple Avenue
Basking Ridge, New Jersey  07920

Michael E. Autera                   Executive Vice President
Bristol-Myers Squibb Company
345 Park Avenue
New York, New York 10154

Ellen V. Futter                     President of The American Museum of
The American Museum of Natural      Natural History
History
Central Park West at 79th Street
New York, NY  10024

Louis V. Gerstner, Jr.              Chairman of the Board and Chief Executive
IBM Corporation                     Officer of IBM Corporation
Old Orchard Road
Armonk, NY  10504

John D. Macomber                    President of JDM Investment Group
JDM Investment Group
2806 N. Street, N.W.
Washington, DC  20007

James D. Robinson III               President of J.D. Robinson Inc.
J.D. Robinson Inc.
126 East 56th Street
New York, NY  10022



CUSIP No.  20741010                                                Page 11 of 15


Andrew C. Sigler                    Chairman and Chief Executive Officer of
Champion International Corporation  Champion International Corporation
One Champion Plaza
Stamford, CT  06921

Louis W. Sullivan, M.D.             President of Morehouse School of Medicine
Morehouse School of Medicine
720 Westview Drive, S.W.
Atlanta, GA  30310-1495

Kenneth E. Weg                      Executive Vice President and President,
Bristol-Myers Squibb Company        Bristol-Myers Squibb Pharmaceutical Group
345 Park Avenue
New York, NY 10154


Officers of Bristol-Myers Squibb Company

Charles A. Heimbold, Jr.            Chairman of the Board, Director, President
                                    and Chief Executive Officer

Michael E. Autera                   Executive Vice President and Director

Harrison M. Bains, Jr.              Treasurer and Vice President, Corporate 
                                     Staff

Samuel L. Barker, Ph.D.             President, Bristol-Myers Squibb U.S.
                                    Pharmaceuticals

Stephen E. Bear                     President, Worldwide Consumer Medicines

Andrew G. Bodnar, M.D.              Vice President, Medical and Legal Affairs,
                                    Corporate Staff

Alice C. Brennan                    Corporate Secretary and Vice President,
                                    Corporate Staff

Jack M. Cooper                      Vice President, Information Management,
                                    Corporate Staff

Peter R. Dolan                      President, Mead Johnson Nutritional Group

Richard A. Druckman                 Vice President, Strategic Planning,
                                    Corporate Staff

Terence N. Furness                  President, Zimmer, Inc.

John D. Glover                      Vice President, Corporate Security,
                                    Corporate Staff



CUSIP No.  20741010                                                Page 12 of 15


Samuel A. Hamad                     President, Bristol-Myers Squibb
                                    Pharmaceuticals - Intercontinental

Donald J. Hayden, Jr.               Senior Vice President, Worldwide Franchise
                                    Management and Business Development

Thomas M. Hellman, Ph.D.            Vice President, Environmental Affairs,
                                    Occupational Health and Safety, Corporate
                                    Staff

E. Lynn Johnson                     Senior Vice President, Corporate Staff 

George P. Kooluris                  Senior Vice President, Corporate
                                    Development, Corporate Staff 

Margaret E. Maruschak               Vice President, Issues Management,
                                    Corporate Staff 

John L. McGoldrick                  General Counsel and Senior Vice President,
                                    Corporate Staff

Michael F. Mee                      Chief Financial Officer and Senior Vice
                                    President, Corporate Staff

Leon E. Rosenberg, M.D.             President, Bristol-Myers Squibb
                                    Pharmaceutical Research Institute

Stephen I. Sadove                   President, Worldwide Clairol

Frederick S. Schiff                 Controller and Vice President, Corporate
                                    Staff

Eileen S. Silvers                   Vice President, Taxes, Corporate Staff

John L. Skule                       Vice President, Public Affairs, Corporate
                                    Staff

Joseph G. Solari, Jr.               President, ConvaTec and President, Bristol-
                                    Myers Squibb Medical Products Group

Charles G. Tharp, Ph.D.             Senior Vice President, Human Resources,
                                    Corporate Staff

Richard L. Thompson                 Vice President, Government Affairs,
                                    Corporate Staff

Joachim H. von Roy                  President, Bristol-Myers Squibb
                                    Pharmaceuticals - Europe



CUSIP No.  20741010                                                Page 13 of 15

Kenneth E. Weg                      Executive Vice President and Director,
                                    President, Bristol-Myers Squibb
                                    Pharmaceutical Group




CUSIP No.  20741010                                                Page 14 of 15

                                   SCHEDULE B

                          Shares of Common Stock Owned

                                     None.




                     Transactions in Shares of Common Stock
                            during the Last 60 Days

                                     None.



CUSIP No.  20741010                                                Page 15 of 15


                                 EXHIBIT INDEX


Exhibit
Number                     Document

1                          Stock  Purchase  Agreement,  dated as of  August  24,
                           1989, between Zimmer, Inc. and CONMED Corporation for
                           all  of  the   outstanding   Common  Stock  of  Aspen
                           Laboratories,  Inc.  (Incorporated  by  reference  to
                           Exhibit  10.2 to  CONMED  Corporation's  Registration
                           Statement on Form S-2 (File No. 33-40455).)

2                          Warrant to Purchase  Common  Stock,  dated August 31,
                           1989,  issued by CONMED  Corporation to Zimmer,  Inc.
                           covering   shares   of   Common   Stock   of   CONMED
                           Corporation.  (Incorporated  by  reference to Exhibit
                           4.6 to CONMED Corporation's Registration Statement on
                           Form S-2 (File No. 33-40455).)